Accelerate Diagnostics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
10-K/A: Accelerate Diagnostics Files Amended 10-K to Include Omitted Executive and Governance Information
Accelerate Diagnostics files an amendment to its 2024 annual report to include previously omitted information regarding directors, executive compensation, security ownership, related transactions, and principal accountant fees.
Accelerate Diagnostics' 10-K filing reveals substantial doubt about its ability to continue as a going concern due to recurring losses and significant debt, prompting a strategic review.
Accelerate Diagnostics, Inc. outlines the details of its registered common stock and preferred stock, including voting rights, dividend entitlements, and anti-takeover provisions, as of December 31, 2023.